Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Myositis autoantibodies: Clinical significance of higher cut- offs using the Euroimmun Research Line Blot.

Cinoku II, Zampeli E, Mavragani CP, Skopouli FN, Moutsopoulos HM.

Arthritis Rheumatol. 2020 Feb 18. doi: 10.1002/art.41228. [Epub ahead of print]

PMID:
32067350
2.

Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity.

Cinoku II, Mavragani CP, Moutsopoulos HM.

Eur J Clin Invest. 2020 Feb;50(2):e13195. doi: 10.1111/eci.13195. Epub 2020 Jan 18. Review.

PMID:
31868918
3.

Sjögren's syndrome: Old and new therapeutic targets.

Mavragani CP, Moutsopoulos HM.

J Autoimmun. 2019 Dec 9:102364. doi: 10.1016/j.jaut.2019.102364. [Epub ahead of print] Review.

PMID:
31831255
4.

Independent association of low IFNλ1 gene expression and type I IFN score/IFNλ1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome.

Flessa CM, Vlachiotis S, Nezos A, Andreakos E, Mavragani CP, Tektonidou MG.

Clin Immunol. 2019 Dec;209:108265. doi: 10.1016/j.clim.2019.108265. Epub 2019 Oct 19.

PMID:
31639447
5.

Drs. Mavragani and Moutsopoulos reply.

Mavragani CP, Moutsopoulos HM.

J Rheumatol. 2020 Jan;47(1):158. doi: 10.3899/jrheum.190837. Epub 2019 Sep 15. No abstract available.

PMID:
31523045
6.

Genetic contributors and soluble mediators in prediction of autoimmune comorbidity.

Nezos A, Evangelopoulos ME, Mavragani CP.

J Autoimmun. 2019 Nov;104:102317. doi: 10.1016/j.jaut.2019.102317. Epub 2019 Aug 20. Review.

PMID:
31444033
7.

Biologics in Sjögren's syndrome.

Skarlis C, Marketos N, Mavragani CP.

Pharmacol Res. 2019 Sep;147:104389. doi: 10.1016/j.phrs.2019.104389. Epub 2019 Aug 12. Review.

PMID:
31415917
8.

Hypertension: An immune related disorder?

Sereti E, Stamatelopoulos KS, Zakopoulos NA, Evangelopoulou A, Mavragani CP, Evangelopoulos ME.

Clin Immunol. 2020 Mar;212:108247. doi: 10.1016/j.clim.2019.108247. Epub 2019 Aug 8.

PMID:
31401215
9.

Type I interferon signature in Sjögren's syndrome: pathophysiological and clinical implications.

Marketos N, Cinoku I, Rapti A, Mavragani CP.

Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):185-191. Epub 2019 Jul 11. Review.

10.

TREX1 variants in Sjogren's syndrome related lymphomagenesis.

Nezos A, Makri P, Gandolfo S, De Vita S, Voulgarelis M, Crow MK, Mavragani CP.

Cytokine. 2019 Jul 17:154781. doi: 10.1016/j.cyto.2019.154781. [Epub ahead of print]

PMID:
31326279
11.

Primary versus Secondary Sjögren Syndrome: Is It Time To Reconsider These Terms?

Mavragani CP, Moutsopoulos HM.

J Rheumatol. 2019 Jul;46(7):665-666. doi: 10.3899/jrheum.180392. No abstract available.

PMID:
31262751
12.

Emerging roles for chemokines and cytokines as orchestrators of immunopathology in Sjögren's syndrome.

Blokland SLM, Flessa CM, van Roon JAG, Mavragani CP.

Rheumatology (Oxford). 2019 Mar 5. pii: key438. doi: 10.1093/rheumatology/key438. [Epub ahead of print]

PMID:
30838419
13.

TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients.

Nezos A, Gkioka E, Koutsilieris M, Voulgarelis M, Tzioufas AG, Mavragani CP.

J Immunol Res. 2018 Dec 19;2018:6923213. doi: 10.1155/2018/6923213. eCollection 2018.

14.

B cells and atherosclerosis in systemic lupus erythematosus.

Koulouri V, Koutsilieris M, Mavragani CP.

Expert Rev Clin Immunol. 2019 Apr;15(4):417-429. doi: 10.1080/1744666X.2019.1571411. Epub 2019 Feb 8.

PMID:
30652925
15.

Study of the incidence of osteoporosis in patients with Sjögren's syndrome (pSS) and investigation of activation of the RANKL /RANK and osteoprotegerin (OPG) system.

Skarlis C, Palli E, Nezos A, Koutsilieris M, Mavragani CP.

Mediterr J Rheumatol. 2018 Dec 18;29(4):224-227. doi: 10.31138/mjr.29.4.224. eCollection 2018 Dec. No abstract available.

16.

Autoantibodies to ox-LDL in Sjögren's syndrome: are they atheroprotective?

Cinoku I, Mavragani CP, Tellis CC, Nezos A, Tselepis AD, Moutsopoulos HM.

Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):61-67. Epub 2018 Aug 13.

17.

Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.

Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM.

Clin Rheumatol. 2019 Jan;38(1):125-132. doi: 10.1007/s10067-018-4267-z. Epub 2018 Aug 25.

PMID:
30145635
18.

Tongue Atrophy in Sjögren Syndrome Patients with Mucosa-associated Lymphoid Tissue Lymphoma: Autoimmune Epithelitis beyond the Epithelial Cells of Salivary Glands?

Zampeli E, Kalogirou EM, Piperi E, Mavragani CP, Moutsopoulos HM.

J Rheumatol. 2018 Nov;45(11):1565-1571. doi: 10.3899/jrheum.180101. Epub 2018 Jul 15.

PMID:
30008454
19.

Anxiety and Extraversion in Lupus-Related Atherosclerosis.

Giannelou M, Tseronis D, Antypa E, Mavragani CP.

Front Psychiatry. 2018 Jun 19;9:246. doi: 10.3389/fpsyt.2018.00246. eCollection 2018.

20.

B-cell activating factor and related genetic variants in lupus related atherosclerosis.

Theodorou E, Nezos A, Antypa E, Ioakeimidis D, Koutsilieris M, Tektonidou M, Moutsopoulos HM, Mavragani CP.

J Autoimmun. 2018 Aug;92:87-92. doi: 10.1016/j.jaut.2018.05.002. Epub 2018 May 31.

PMID:
29859654
21.

Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren's syndrome.

Kampolis CF, Fragkioudaki S, Mavragani CP, Zormpala A, Samakovli A, Moutsopoulos HM.

Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):94-101. Epub 2018 May 29.

22.

Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.

Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT.

Semin Arthritis Rheum. 2018 Dec;48(3):467-474. doi: 10.1016/j.semarthrit.2018.02.014. Epub 2018 Feb 23.

PMID:
29555348
23.

Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients.

Thomas K, Lazarini A, Kaltsonoudis E, Drosos A, Papalopoulos I, Sidiropoulos P, Katsimbri P, Boumpas D, Tsatsani P, Gazi S, Fragkiadaki K, Tektonidou M, Sfikakis PP, Pantazi L, Boki KA, Grika EP, Vlachoyiannopoulos PG, Karagianni K, Sakkas LI, Dimitroulas T, Garyfallos A, Kassimos D, Evangelatos G, Iliopoulos A, Areti M, Georganas C, Melissaropoulos K, Georgiou P, Vounotrypidis P, Ntelis K, Mavragani CP, Bournazos I, Katsifis G, Mavrommatis C, Kitas GD, Vassilopoulos D.

Mediterr J Rheumatol. 2018 Mar 19;29(1):27-37. doi: 10.31138/mjr.29.1.27. eCollection 2018 Mar.

24.

Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis.

Giannelou M, Nezos A, Fragkioudaki S, Kasara D, Maselou K, Drakoulis N, Ioakeimidis D, Moutsopoulos HM, Mavragani CP.

Clin Immunol. 2018 Aug;193:110-117. doi: 10.1016/j.clim.2018.02.014. Epub 2018 Mar 6.

PMID:
29501539
25.

Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Golemati CV, Mavragani CP, Lionaki S, Karaiskos D, Moutsopoulos HM.

Front Psychiatry. 2017 Dec 15;8:286. doi: 10.3389/fpsyt.2017.00286. eCollection 2017.

26.

Psychological comorbidities associated with subclinical atherosclerosis in Greek patients with primary Sjögren's syndrome: a potential contribution of sleep impairment.

Karageorgas T, Ioakeimidis D, Mavragani CP.

Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):68-72. Epub 2017 Nov 14.

27.

Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes.

Mavragani CP, Nezos A, Sagalovskiy I, Seshan S, Kirou KA, Crow MK.

J Autoimmun. 2018 Mar;88:75-82. doi: 10.1016/j.jaut.2017.10.004. Epub 2017 Oct 23.

28.

Type I interferonopathy in a young adult.

Manoussakis MN, Mavragani CP, Nezos A, Zampeli E, Germenis A, Moutsopoulos HM.

Rheumatology (Oxford). 2017 Dec 1;56(12):2241-2243. doi: 10.1093/rheumatology/kex316. No abstract available.

PMID:
28968819
29.

Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome.

Nezos A, Cinoku I, Mavragani CP, Moutsopoulos HM.

Clin Immunol. 2017 Oct;183:300-303. doi: 10.1016/j.clim.2017.09.012. Epub 2017 Sep 14.

PMID:
28919520
30.

MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome.

Fragkioudaki S, Nezos A, Souliotis VL, Chatziandreou I, Saetta AA, Drakoulis N, Tzioufas AG, Voulgarelis M, Sfikakis PP, Koutsilieris M, Crow MK, Moutsopoulos HM, Mavragani CP.

Sci Rep. 2017 Aug 4;7(1):7354. doi: 10.1038/s41598-017-07347-w.

31.

Cardiovascular disease in systemic lupus erythematosus: A comprehensive update.

Giannelou M, Mavragani CP.

J Autoimmun. 2017 Aug;82:1-12. doi: 10.1016/j.jaut.2017.05.008. Epub 2017 Jun 9. Review.

PMID:
28606749
32.

Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome.

Quartuccio L, Mavragani CP, Nezos A, Gandolfo S, Tzioufas AG, De Vita S.

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):719-720. Epub 2017 Mar 8. No abstract available.

PMID:
28281461
33.

Mechanisms and New Strategies for Primary Sjögren's Syndrome.

Mavragani CP.

Annu Rev Med. 2017 Jan 14;68:331-343. doi: 10.1146/annurev-med-043015-123313. Review.

PMID:
28099084
34.

Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores.

Vlachogiannis NI, Nezos A, Tzioufas AG, Koutsilieris M, Moutsopoulos HM, Mavragani CP.

Clin Immunol. 2016 Dec;173:157-160. doi: 10.1016/j.clim.2016.10.015. Epub 2016 Nov 1.

PMID:
27810512
35.

Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease.

Mavragani CP, Sagalovskiy I, Guo Q, Nezos A, Kapsogeorgou EK, Lu P, Liang Zhou J, Kirou KA, Seshan SV, Moutsopoulos HM, Crow MK.

Arthritis Rheumatol. 2016 Nov;68(11):2686-2696. doi: 10.1002/art.39795.

36.

Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use.

Fragkioudaki S, Mavragani CP, Moutsopoulos HM.

Medicine (Baltimore). 2016 Jun;95(25):e3766. doi: 10.1097/MD.0000000000003766.

37.

Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis.

Lionaki S, Mavragani CP, Karras A, Liapis G, Somarakis G, Boletis JN, Drosos A, Tzioufas AG, Guillevin L, Moutsopoulos HM.

J Autoimmun. 2016 Aug;72:57-64. doi: 10.1016/j.jaut.2016.05.004. Epub 2016 May 15.

PMID:
27194577
38.

Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies.

Ekholm L, Vosslamber S, Tjärnlund A, de Jong TD, Betteridge Z, McHugh N, Plestilova L, Klein M, Padyukov L, Voskuyl AE, Bultink IE, Michiel Pegtel D, Mavragani CP, Crow MK, Vencovsky J, Lundberg IE, Verweij CL.

Scand J Immunol. 2016 Aug;84(2):100-9. doi: 10.1111/sji.12449.

39.

Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis.

Nezos A, Mavragani CP.

J Immunol Res. 2015;2015:754825. doi: 10.1155/2015/754825. Epub 2015 Oct 15. Review.

40.

Fatigue in Primary Sjögren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations.

Karageorgas T, Fragioudaki S, Nezos A, Karaiskos D, Moutsopoulos HM, Mavragani CP.

Arthritis Care Res (Hoboken). 2016 Jan;68(1):123-31. doi: 10.1002/acr.22720.

41.

Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP.

J Autoimmun. 2015 Sep;63:47-58. doi: 10.1016/j.jaut.2015.07.002. Epub 2015 Jul 14.

42.

A BAFF receptor His159Tyr mutation in Sjögren's syndrome-related lymphoproliferation.

Papageorgiou A, Mavragani CP, Nezos A, Zintzaras E, Quartuccio L, De Vita S, Koutsilieris M, Tzioufas AG, Moutsopoulos HM, Voulgarelis M.

Arthritis Rheumatol. 2015 Oct;67(10):2732-41. doi: 10.1002/art.39231.

43.

Clinical and laboratory predictors of distinct histopathogical features of lupus nephritis.

Mavragani CP, Fragoulis GE, Somarakis G, Drosos A, Tzioufas AG, Moutsopoulos HM.

Medicine (Baltimore). 2015 May;94(21):e829. doi: 10.1097/MD.0000000000000829.

44.

Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations.

Gravani F, Papadaki I, Antypa E, Nezos A, Masselou K, Ioakeimidis D, Koutsilieris M, Moutsopoulos HM, Mavragani CP.

Arthritis Res Ther. 2015 Apr 11;17:99. doi: 10.1186/s13075-015-0613-6.

45.

Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.

Papageorgiou A, Ziogas DC, Mavragani CP, Zintzaras E, Tzioufas AG, Moutsopoulos HM, Voulgarelis M.

PLoS One. 2015 Feb 27;10(2):e0116189. doi: 10.1371/journal.pone.0116189. eCollection 2015.

46.

Elevated IgG4 serum levels among primary Sjögren's syndrome patients: do they unmask underlying IgG4-related disease?

Mavragani CP, Fragoulis GE, Rontogianni D, Kanariou M, Moutsopoulos HM.

Arthritis Care Res (Hoboken). 2014 May;66(5):773-7. doi: 10.1002/acr.22216.

47.

IgG4-related disease: a rheumatologist's perspective.

Soliotis F, Mavragani CP, Plastiras SC, Rontogianni D, Skopouli FN, Moutsopoulos HM.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5):724-7. Epub 2014 Jul 28.

PMID:
25068679
48.

Sjögren syndrome.

Mavragani CP, Moutsopoulos HM.

CMAJ. 2014 Oct 21;186(15):E579-86. doi: 10.1503/cmaj.122037. Epub 2014 Feb 24. Review. No abstract available.

49.

Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome.

Voulgarelis M, Mavragani CP, Xu L, Treon SP, Moutsopoulos HM.

Genes Immun. 2014 Jan;15(1):54-6. doi: 10.1038/gene.2013.54. Epub 2013 Oct 24.

PMID:
24153350
50.

Sjögren's syndrome.

Mavragani CP, Moutsopoulos HM.

Annu Rev Pathol. 2014;9:273-85. doi: 10.1146/annurev-pathol-012513-104728. Epub 2013 Sep 18. Review.

PMID:
24050623

Supplemental Content

Loading ...
Support Center